RECURSION PHARMACEUTICALS, INC. — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Recursion Pharmaceuticals priced a $200 million underwritten offering of 61,540,000 shares of Class A common stock at $3.25 per share (gross proceeds; net after fees ~$188–192M). Underwriters: Leerink Partners, Goldman Sachs, Morgan Stanley, Evercore (joint bookrunners); Needham (lead manager). Closing expected ~October 16, 2026. Investors include Janus Henderson, Invus, Longaeva, ARK, Driehaus, and others. Proceeds will extend cash runway into 2029.
Why this rating
Meaningful secondary offering (~10% dilution) strengthens balance sheet at $2B market cap; extends runway and funds clinical programs. Positive but not transformational.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.